[ExI] 'Magic mushroom' compound may work just as well as antidepressants, small study finds
nuala.t at gmail.com
Fri Apr 16 16:00:11 UTC 2021
They can't patent it but if medicinal marijuana can get passed then I don't
see why this can't, except they have to spend money and roll out an
approval system. Obviously costing a lot to hire the right people, federal
courts, FDA, etc. Etc.
On Sat., Apr. 17, 2021, 00:55 William Flynn Wallace via extropy-chat, <
extropy-chat at lists.extropy.org> wrote:
> Here's the problem: only Big PHarma has the money, often billions needed,
> to fully test a drug and get FDA approval, and they are not going to do
> that for this type of drug -can't make any money from it - can't patent it,
> etc. bill w
> On Fri, Apr 16, 2021 at 9:47 AM Nuala Thomson via extropy-chat <
> extropy-chat at lists.extropy.org> wrote:
>> Micro dosing has been around for ages. I think LSD yields similar results
>> and micro dosing mdma has helped couples/marriages.
>> The problem is getting this sort of therapy approved as mainstream and
>> more providers able to administer it.
>> Regardless, I'm definitely not adverse to a "reset" once or twice a year.
>> I think it's beneficial even outside of a therapy session as I find it
>> helps with my own spirituality and exploration.
>> On Fri., Apr. 16, 2021, 21:57 John Grigg via extropy-chat, <
>> extropy-chat at lists.extropy.org> wrote:
>>> "Psilocybin, the hallucinogen found in "magic mushrooms," may work just
>>> as well as a common antidepressant drug at treating symptoms of depression,
>>> a small new study suggests.
>>> The study found that people who took psilocybin twice under the
>>> supervision of psychiatrists showed similar reductions in *depression*
>>> symptoms — based on scores on a survey — compared with people who took a
>>> six-week course of the antidepressant escitalopram. And those in the
>>> psilocybin group were more likely to report remission from depression
>>> symptoms, compared with those in the escitalopram group, according to the
>>> study, published Wednesday (April 14) in *The New England Journal of
>>> Medicine* <http://www.nejm.org/doi/full/10.1056/NEJMoa2032994>.
>>> "One of the most important aspects of this work is that people can
>>> clearly see the promise of properly delivered psilocybin therapy by viewing
>>> it compared with a more familiar, established treatment in the same study,"
>>> study lead author Robin Carhart-Harris, head of the Centre for Psychedelic
>>> Research at Imperial College London, *said in a statement*
>>> "Psilocybin performed very favourably in this head-to-head [trial]."
>>> extropy-chat mailing list
>>> extropy-chat at lists.extropy.org
>> extropy-chat mailing list
>> extropy-chat at lists.extropy.org
> extropy-chat mailing list
> extropy-chat at lists.extropy.org
-------------- next part --------------
An HTML attachment was scrubbed...
More information about the extropy-chat